Xu Tianlei, Yu Zhuo, Zhang Qian, Liu Botao, Li Yuanxin, Wang Feng
Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Transl Cancer Res. 2021 Dec;10(12):5028-5039. doi: 10.21037/tcr-21-1480.
The presence of tumor deposits (TDs) is only considered in the absence of lymph node metastases (LNMs) in the current TNM staging system. However, the prognostic value of TDs when concomitant with LNM for rectal cancer after neoadjuvant chemoradiotherapy (NCRT) remains unclear. This study aimed to evaluate the prognostic value of TDs and when concomitant with LNMs in rectal cancer after NCRT.
Patients with rectal cancer who had received NCRT between 2010 and 2016 were obtained from the Surveillance, Epidemiology and End Results (SEER) 18 (year range, 1975-2016) database. Data were extracted on the following: age, sex, race, TNM stage, total LNs harvested, positive LNs, histologic type, perineural invasion, grade, carcinoma embryonic antigen status, TD number, and cancer-specific survival (CSS) rates. The primary objective was to determine the prognostic impact of TDs on CSS. The effect of the addition of TD to the LNM count for a novel N stage was also evaluated. Univariate and multivariate analyses were performed using the Kaplan-Meier method and Cox models.
Of 9,620 patients, 865 (9.0%) had TDs. TD-positive patients showed a worse prognosis than TD-negative patients (HR =2.39, 95% CI: 2.04-2.80, P<0.001), and multivariate analysis showed that the presence of TDs was an independent poor prognostic factor (HR =1.41, 95% CI: 1.19-1.67, P<0.001). Regarding the LN status, TDs were associated with a higher risk of cancer-specific death in the LNM- group (HR =2.43, 95% CI: 1.86-3.18, P<0.001), M1 group (HR =1.51, 95% CI: 1.08-2.10, P<0.001), and ypN1 group (HR =2.08, 95% CI: 1.61-2.70, P<0.001), but not in the ypN2 group (HR =0.97, 95% CI: 0.69-1.36, P=0.84). Patients with concomitant TDs and LNM showed significantly worse survival than those with TDs or LNM alone (5-year CSS: 48.2%, 72.2%, and 67.8%, respectively). The 5-year CSS rates were 86.2%, 77.4%, 65.1%, 53.8%, and 46.5% for the novel N0, N1a, N1b, N2a, and N2b groups, respectively (P<0.05 across all groups). Time dependent receiver operating characteristic curve analysis and decision curve analysis showed that the novel N stage was superior to the current ypN stage.
The presence of TDs is an independent poor prognostic factor for LARC patients after NCRT. The concomitant presence of TDs and LNM indicates a significantly worse survival, and the addition of TD to LNM may help to better prompt appropriate risk stratification.
在当前的TNM分期系统中,仅在无淋巴结转移(LNM)的情况下才考虑肿瘤结节(TD)的存在。然而,新辅助放化疗(NCRT)后TD与LNM并存时对直肠癌的预后价值仍不清楚。本研究旨在评估NCRT后TD以及TD与LNM并存时对直肠癌的预后价值。
从监测、流行病学和最终结果(SEER)18(年份范围,1975 - 2016)数据库中获取2010年至2016年期间接受过NCRT的直肠癌患者。提取以下数据:年龄、性别、种族、TNM分期、切除的淋巴结总数、阳性淋巴结、组织学类型、神经周围侵犯、分级、癌胚抗原状态、TD数量和癌症特异性生存(CSS)率。主要目的是确定TD对CSS的预后影响。还评估了将TD添加到LNM计数中对新的N分期的影响。使用Kaplan - Meier方法和Cox模型进行单因素和多因素分析。
在9620例患者中,865例(9.0%)有TD。TD阳性患者的预后比TD阴性患者差(HR = 2.39,95%CI:2.04 - 2.80,P < 0.001),多因素分析表明TD的存在是一个独立的不良预后因素(HR = 1.41,95%CI:1.19 - 1.67,P < 0.001)。关于淋巴结状态,在LNM -组(HR = 2.43,95%CI:1.86 - 3.18,P < 0.001)、M1组(HR = 1.51,95%CI:1.08 - 2.10,P < 0.001)和ypN1组(HR = 2.08,95%CI:1.61 - 2.70,P < 0.001)中,TD与癌症特异性死亡风险较高相关,但在ypN2组中并非如此(HR = 0.97,95%CI:0.69 - 1.36,P = 0.84)。TD与LNM并存患者的生存率明显低于单独有TD或LNM的患者(5年CSS分别为:48.2%、72.2%和67.8%)。新的N0、N1a、N1b、N2a和N2b组的5年CSS率分别为86.2%、77.4%、65.1%、53.8%和46.5%(所有组间P < 0.05)。时间依赖性受试者工作特征曲线分析和决策曲线分析表明,新的N分期优于当前的ypN分期。
TD的存在是NCRT后局部晚期直肠癌(LARC)患者的一个独立不良预后因素。TD与LNM并存表明生存率明显更差,将TD添加到LNM中可能有助于更好地进行适当的风险分层。